Lung CancerBCBPoumonNCT07085429
Development of Clinical and Biological Database on Bronchial Cancer
A study testing Blood and tissue sampling in people with Lung Cancer and Bronchial Cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle at 1 site in France.
Trial summary
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer, Bronchial Cancer
- What is being tested?
- Blood and tissue sampling
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 750 participants
- Where
- 1 siteFrance
- Study dates
- 25 Nov 2025to Sep 2040
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patient aged over 18 years,
- Histologically or cytologically confirmed bronchial cancer,
- Treatment-naïve patient for the current cancer,
- Patient who has provided informed, written, and explicit consent,
- Patient affiliated with the French national health insurance system.
Who cannot join
- Patient with a WHO performance status ≥ 3,
- Pregnant and/or breastfeeding woman,
- Patient with a history of other cancers within the 5 years preceding inclusion,
- Patient for whom regular follow-up is considered impossible due to psychological, familial, social, or geographic reasons,
- Patient under legal protection (guardianship, curatorship, or judicial protection).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Marc Ychou, MD, PhD, 467613066 ext. +33, marc.ychou@icm.unicancer.fr
Aurore MOUSSION, 467613102 ext. +33, aurore.moussion@icm.unicancer.fr
About this study
Official title: Development of a Prospective Monocentric Clinico-Biological Database for Bronchial Cancer
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.
Read the detailed description
Lung cancer is the leading cause of cancer-related mortality and the third most commonly diagnosed cancer. In France in 2018, it accounted for 46,363 new cases and 33,117 deaths. The overall 5-year survival rate across all stages and sexes is 20%.
Diagnosis is most often made at the metastatic stage, which significantly worsens the prognosis. Since 2020, the standard treatment for such cases has been the administration of intravenous chemo-immunotherapy, in the absence of a molecular alteration that allows for access to an oral targeted therapy. Immunotherapy and targeted therapies have considerably improved the prognosis for some patients, but the vast majority experience therapeutic resistance, either early or delayed.
The prognostic and predictive mechanisms of treatment response are poorly understood and vary greatly between histological and molecular subtypes. It is therefore crucial to gain a better understanding of these mechanisms in order to ultimately identify new therapeutic avenues to improve patient outcomes.
The first step in this process is to establish a tissue and blood biobank from patients with bronchial carcinoma (both small-cell and non-small-cell) treated at our center.
The Clinical Biological DataBase (BCB) is a tool:
- for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials;
- to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations;
- to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.
- Conditions
- Lung Cancer, Bronchial Cancer
- Being tested
- Blood and tissue sampling
- Medical subject headings
- Lung Neoplasms, Carcinoma, Bronchogenic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood and tissue samplingBiological
Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.
During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected:
- before any therapeutic intervention (T1) for a total volume of 36mL,
- prior to surgery (T-Surg) for a total volume of 24mL,
- at each progression (T2a, b, c…) for a total volume of 24mL,
- at the end of follow-up (T3) for a total volume of 24mL.
| Study group | Role | What they receive |
|---|---|---|
| Bronchial cancer | Experimental | Additionnal samples from routine care of different natures (blood, tumor tissue ans healthy tissue) and standardized clinical data will be entered into a database. Receives: Biological: Blood and tissue sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients who consent to participate in the study
the proportion of patients who consent to participate in the study among the screened patients
Measured: through study completion : an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jul 2025
- Study start25 Nov 2025
- Primary completionSep 2030 (estimated)
- Study completionSep 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Institut du Cancer de Montpellier - Val d'AurelleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07085429
- Sponsor's protocol ID
- PROICM 2021-11 BPO
- Acronym
- BCBPoumon
- Status last verified
- Nov 2026
- First submitted
- 2 Jul 2025
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Prospective Monocentric Clinico-Biological Database for Bronchial Cancer
- ClinicalTrials.gov ID
- NCT07085429
- Acronym / sponsor ID
- BCBPoumon / PROICM 2021-11 BPO
- Conditions
- Lung Cancer, Bronchial Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'AurelleUniversity, hospital or other
- Study start
- 25 Nov 2025 (actual)
- Primary completion
- Sep 2030 (estimated)
- Study completion
- Sep 2040 (estimated)
- First posted
- 25 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.
Detailed description
Lung cancer is the leading cause of cancer-related mortality and the third most commonly diagnosed cancer. In France in 2018, it accounted for 46,363 new cases and 33,117 deaths. The overall 5-year survival rate across all stages and sexes is 20%.
Diagnosis is most often made at the metastatic stage, which significantly worsens the prognosis. Since 2020, the standard treatment for such cases has been the administration of intravenous chemo-immunotherapy, in the absence of a molecular alteration that allows for access to an oral targeted therapy. Immunotherapy and targeted therapies have considerably improved the prognosis for some patients, but the vast majority experience therapeutic resistance, either early or delayed.
The prognostic and predictive mechanisms of treatment response are poorly understood and vary greatly between histological and molecular subtypes. It is therefore crucial to gain a better understanding of these mechanisms in order to ultimately identify new therapeutic avenues to improve patient outcomes.
The first step in this process is to establish a tissue and blood biobank from patients with bronchial carcinoma (both small-cell and non-small-cell) treated at our center.
The Clinical Biological DataBase (BCB) is a tool:
- for research in analytical and public health epidemiology, biological research and for the development of data useful for clinical research and therapeutic trials;
- to help scientists understand and explain phenomena ranging from the interaction of molecules to the whole metabolism of the organism in normal and pathological situations;
- to identify potential strategies for prevention, diagnosis, management and analysis of cancer subtypes.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Bronchial cancer | Experimental | Biological: Blood and tissue samplingAdditionnal samples from routine care of different natures (blood, tumor tissue ans healthy tissue) and standardized clinical data will be entered into a database. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female patient aged over 18 years,
- Histologically or cytologically confirmed bronchial cancer,
- Treatment-naïve patient for the current cancer,
- Patient who has provided informed, written, and explicit consent,
- Patient affiliated with the French national health insurance system.
Key exclusion criteria (5 listed)
- Patient with a WHO performance status ≥ 3,
- Pregnant and/or breastfeeding woman,
- Patient with a history of other cancers within the 5 years preceding inclusion,
- Patient for whom regular follow-up is considered impossible due to psychological, familial, social, or geographic reasons,
- Patient under legal protection (guardianship, curatorship, or judicial protection).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood and tissue samplingTissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected: * before any therapeutic intervention (T1) for a total volume of 36mL, * prior to surgery (T-Surg) for a total volume of 24mL, * at each progression (T2a, b, c…) for a total volume of 24mL, * at the end of follow-up (T3) for a total volume of 24mL. | Biological | Bronchial cancer |
Primary outcome
Proportion of patients who consent to participate in the study
Time frame: through study completion : an average of 1 year
the proportion of patients who consent to participate in the study among the screened patients
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood and tissue sampling in people with Lung Cancer and Bronchial Cancer, run by Institut du Cancer de Montpellier - Val d'Aurelle at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emmanuelle TEXIER (467613102 ext. +33, emmanuelle.texier@icm.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients who consent to participate in the study (time frame: through study completion : an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.